Newsroom

Work begins on Alvotech-CCHN joint venture in China

Posted on 25.2.2019 in: Featured news

Following the late 2018 announcement that Alvotech was to enter into a joint venture with Changchun High & New Technology Industries Group Inc (“CCHN”), representatives from the two companies met up last week to discuss the groundbreaking of the new facility.

Representatives from CCHN & Alvotech., Among them Mr. An Jixiang, EVP at CCHN, , Mr. Robert Wessman, Alvotech’s founder & Alvotech’s CEO, Mr. Rasmus Rojkjaer

In a board meeting held at CCHN’s office in Changchun, Rasmus Rojkjaer and Robert Wessman, CEO and Founder of Alvotech respectively, discussed the partnership’s ambition of becoming a leading force in China over the coming years, offering highest quality biopharmaceuticals at affordable prices.

To achieve that goal, the companies are planning joint investments of more than $200 million, for the registration of six Alvotech biosimilar products in China and the construction of a state-of-the-art biopharmaceutical manufacturing facility in Changchun. Within the coming months, construction work will commence, and the joint venture will be on its way bringing the very best-in-class treatments to patients in China.

Board members exited the meeting with an even greater confidence that the joint venture will secure a favorable position in China’s biosimilar market in the future.

Exciting times lie ahead!

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.